We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Transient Thyroiditis after Treatment with Lenalidomide in a Patient with Metastatic Renal Cell Carcinoma.
- Authors
Stein, Emily M.; Rivera, Cristina
- Abstract
Lenalidomide, a recently developed immunomodulatory drug, shares the antiangiogenic and antitumor properties of thalidomide. While there is a known association between thalidomide and hypothyroidism, to our knowledge, there have been no prior reports of thyrotoxicosis associated with thalidomide or lenalidomide treatment. Herein, we report the case of a patient who developed transient thyrotoxicosis while receiving lenalidomide in a clinical trial for metastatic renal cell carcinoma. The time course and biochemical features of this patient's presentation are most consistent with immune-mediated subacute destructive thyroiditis. This case highlights the importance of monitoring thyroid function in the growing number of patients being treated with lenalidomide.
- Subjects
THYROIDITIS; THYROID gland function tests; HYPOTHYROIDISM; THALIDOMIDE; THYROID antagonists; GENETICS; THERAPEUTICS
- Publication
Thyroid, 2007, Vol 17, Issue 7, p681
- ISSN
1050-7256
- Publication type
Case Study
- DOI
10.1089/thy.2006.0294